- Home
- ICE vs KZR Comparison
ICE vs KZR Comparison
Compare ICE & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICE
- KZR
- Stock Information
- Founded
- ICE 2000
- KZR 2015
- Country
- ICE United States
- KZR United States
- Employees
- ICE N/A
- KZR N/A
- Industry
- ICE Investment Bankers/Brokers/Service
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- ICE Finance
- KZR Health Care
- Exchange
- ICE Nasdaq
- KZR Nasdaq
- Market Cap
- ICE 99.5B
- KZR 29.7M
- IPO Year
- ICE 2005
- KZR 2018
- Fundamental
- Price
- ICE $172.21
- KZR $3.74
- Analyst Decision
- ICE Buy
- KZR Hold
- Analyst Count
- ICE 13
- KZR 2
- Target Price
- ICE $194.38
- KZR $9.00
- AVG Volume (30 Days)
- ICE 2.5M
- KZR 30.5K
- Earning Date
- ICE 10-30-2025
- KZR 11-11-2025
- Dividend Yield
- ICE 1.12%
- KZR N/A
- EPS Growth
- ICE 28.91
- KZR N/A
- EPS
- ICE 5.21
- KZR N/A
- Revenue
- ICE $9,688,000,000.00
- KZR N/A
- Revenue This Year
- ICE $8.72
- KZR N/A
- Revenue Next Year
- ICE $5.57
- KZR N/A
- P/E Ratio
- ICE $33.02
- KZR N/A
- Revenue Growth
- ICE 9.95
- KZR N/A
- 52 Week Low
- ICE $142.29
- KZR $3.62
- 52 Week High
- ICE $189.35
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- ICE 36.90
- KZR 35.98
- Support Level
- ICE $170.25
- KZR $3.76
- Resistance Level
- ICE $176.59
- KZR $4.05
- Average True Range (ATR)
- ICE 2.40
- KZR 0.13
- MACD
- ICE -0.19
- KZR -0.01
- Stochastic Oscillator
- ICE 26.10
- KZR 6.82
About ICE Intercontinental Exchange Inc.
Intercontinental Exchange is a vertically integrated operator of financial exchanges and provides ancillary data products. Though the company is probably best known for its ownership of the New York Stock Exchange, which it acquired in 2013, ICE operates a large derivatives exchange, too. The company's largest commodity futures product is the ICE Brent crude futures contract. In addition to the exchanges business, which is about 54% of net revenue, Intercontinental Exchange has used a series of acquisitions to create its mortgage technology business (22% of net revenue) and fixed-income and data services segment (24% of net revenue).
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.